AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20360622 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (normal lipid profile)
Number of subjects: 125
Study 18790510 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 251
Study 18790510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 15620502 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable sutures
Number of subjects: 33
Study 15620502 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable sutures
Number of subjects: 33
Study 11843506 — intervention group
Group type: EXPERIMENTAL
Intervention: Homograft (group H)
Number of subjects: 137
Study 11843506 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Freestyle bioprosthesis (group F)
Number of subjects: 137
Study 10102947 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day triple therapy with amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d., and lansoprazole 30 mg b.d.
Number of subjects: 30
Study 10102947 — intervention group
Group type: COMPARATOR
Intervention: 1-day quadruple therapy with amoxycillin 2000 mg q.d.s., clarithromycin 500 mg q.d.s., lansoprazole 30 mg t.d.s., and bismuth subcitrate 240 mg q.d.s.
Number of subjects: 30
Study 10102947 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day triple therapy (same as above) for re-treatment of patients who failed 1-day treatment.
Number of subjects: 30
Study 8537068 — intervention group
Group type: EXPERIMENTAL
Intervention: Right and left anterior atrial branches and right and left posterior atrial branches
Number of subjects: 130
Study 8537068 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of coronary arteries ramifications
Number of subjects: 130
Study 8537068 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastomoses between branches of the right and left coronary arteries
Number of subjects: 130
Study 2299563 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Pen biometric ruler
Number of subjects: 207
Study 2299563 — intervention group
Group type: COMPARATOR
Intervention: Kretz 7200 MA A-scan unit
Number of subjects: 207
Study 31793529 — intervention group
Group type: EXPERIMENTAL
Intervention: Frinozol nasal spray (Phenylephrine + Cetyrizine) 2 sprays per each nostril three times a day for 7 days
Number of subjects: 134
Study 31793529 — intervention group
Group type: COMPARATOR
Intervention: Vibrocil 2 sprays per each nostril three times a day for 7 days
Number of subjects: 134
Study 31793529 — intervention group
Group type: EXPERIMENTAL
Intervention: Frinozol nasal spray (Phenylephrine + Cetyrizine)
Number of subjects: 134
Study 31793529 — intervention group
Group type: COMPARATOR
Intervention: Vibrocil
Number of subjects: 134
Study 28202383 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored program of physical therapy focused on progressive training in strength, balance, and gait for a period of 3 months, along with screening and follow‐up for vision, polypharmacy, and environmental hazards
Number of subjects: 354
Study 28202383 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored program of physical therapy
Number of subjects: 354
Study 28202383 — intervention group
Group type: COMPARATOR
Intervention: Usual care prescribed by a physician and educational materials on falls prevention
Number of subjects: 354
Study 25884192 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic strain Lactobacillus paracasei SD1
Number of subjects: 60
Study 25884192 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 60
Study 24020899 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone 45 mg daily
Number of subjects: 34
Study 24020899 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 21949991 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg ginaton by vein, once a day for 14 days (Group A)
Number of subjects: 91
Study 21949991 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg Alprostadil injection by vein, once a day for 14 days (Group B)
Number of subjects: 91
Study 21949991 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg Alprostadil injection and ginaton by vein, once a day for 14 days (Group C)
Number of subjects: 91
Study 19416095 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 1% (60 microg kg(‐1) body-weight)
Number of subjects: 40
Study 19416095 — intervention group
Group type: EXPERIMENTAL
Intervention: Cevimeline (30 mg)
Number of subjects: 40
Study 17876389 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal pole signal abnormality (TPA) in patients with HS
Number of subjects: 120
Study 14986190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint training (S)
Number of subjects: 17
Study 14986190 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 17
Study 11564829 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 administered subcutaneously for 28 days
Number of subjects: 0
Study 11564829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9563670 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate Aqueous Nasal Spray (FPANS)
Number of subjects: 42
Study 9563670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7970533 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) at one sitting
Number of subjects: 29
Study 7970533 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) at two sittings
Number of subjects: 29
Study 3044575 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 0
Study 3044575 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 0
Study 31747481 — intervention group
Group type: EXPERIMENTAL
Intervention: High Definition Laryngoscopy (HDL)
Number of subjects: 36
Study 31747481 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic Laryngoscopy (FOL)
Number of subjects: 36
Study 28320220 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqiqubai granule
Number of subjects: 233
Study 28320220 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser
Number of subjects: 233
Study 28320220 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatments (Yiqiqubai granule + 308-nm excimer laser)
Number of subjects: 233
Study 28320220 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 233
Study 24930619 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioembolization with yttrium-90 resin microspheres followed by sorafenib (200 mg twice daily escalating to 400 mg twice daily)
Number of subjects: 40
Study 24930619 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib only (matching dose schedule to the intervention arm)
Number of subjects: 40
Study 24930619 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioembolization plus sorafenib
Number of subjects: 40
Study 24930619 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib only
Number of subjects: 40
Study 23444220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus gemcitabine/capecitabine
Number of subjects: 160
Study 23444220 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine/capecitabine
Number of subjects: 160
Study 23444220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 160
Study 23444220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 21238993 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 210
Study 21238993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 17635103 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise at 60% of VO2peak for 30-120 min expending 1.28-5.76 MJ
Number of subjects: 30
Study 17635103 — intervention group
Group type: COMPARATOR
Intervention: Rest (control group)
Number of subjects: 30
Study 16877419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg three times a day for two periods of 5 days)
Number of subjects: 20
Study 16877419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12917202 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (n = 25)
Number of subjects: 53
Study 12917202 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 28)
Number of subjects: 53
Study 10718775 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (5 mg)
Number of subjects: 6
Study 10718775 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous bolus morphine (5 mg)
Number of subjects: 6
Study 10718775 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous infusion morphine (5 mg)
Number of subjects: 6
Study 8938809 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicryl suture
Number of subjects: 6
Study 8938809 — intervention group
Group type: COMPARATOR
Intervention: Fibrin glue
Number of subjects: 6
Study 1525789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg TID
Number of subjects: 60
Study 1525789 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg TID
Number of subjects: 60
Study 1525789 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg BID
Number of subjects: 60
Study 3885848 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml of intradermal BCG vaccine
Number of subjects: 155
Study 3885848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 3885848 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml of intradermal BCG vaccine (second inoculation)
Number of subjects: 155
Study 28882076 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycling intervention over 12 weeks
Number of subjects: 0
Study 28882076 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 28851799 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop electrosurgical excision procedure (LEEP)
Number of subjects: 0
Study 28851799 — intervention group
Group type: COMPARATOR
Intervention: Cold knife cone biopsy (CKC)
Number of subjects: 0
Study 26677350 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (30 g)
Number of subjects: 68
Study 26677350 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric carbohydrates (maltodextrin)
Number of subjects: 68
Study 26677350 — intervention group
Group type: COMPARATOR
Intervention: Protein + carbohydrates
Number of subjects: 68
Study 23374002 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% nystatin
Number of subjects: 158
Study 23374002 — intervention group
Group type: COMPARATOR
Intervention: 2.5% sodium bicarbonate
Number of subjects: 158
Study 23374002 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 158
Study 21601481 — intervention group
Group type: EXPERIMENTAL
Intervention: Target Hb value in normal range (130‐149 g/l), group 2, n=46
Number of subjects: 89
Study 21601481 — intervention group
Group type: COMPARATOR
Intervention: Target Hb value in subnormal range (110‐129 g/l), group 1, n=43
Number of subjects: 89
Study 18930977 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening (PGS) using FISH for chromosomes X, Y, 13, 16, 18, 21, 22
Number of subjects: 120
Study 18930977 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGS)
Number of subjects: 120
Study 16497643 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (orchidopexy) at 9 months
Number of subjects: 149
Study 16497643 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment (control group) at 3 years
Number of subjects: 149
Study 15240203 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐assisted retraining of memory and attention (study arm)
Number of subjects: 82
Study 15240203 — intervention group
Group type: COMPARATOR
Intervention: Visuo‐constructional and visuo‐motor coordination (control arm)
Number of subjects: 82
Study 11565517 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (300 mg daily)
Number of subjects: 1715
Study 11565517 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (10 mg daily)
Number of subjects: 1715
Study 11565517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1715
Study 9274477 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fundic wrap (Nissen-Rossetti)
Number of subjects: 33
Study 9274477 — intervention group
Group type: COMPARATOR
Intervention: 180 degrees semifundoplication (Toupet)
Number of subjects: 33
Study 9274477 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen-Rossetti
Number of subjects: 33
Study 8297658 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐HPR 200 mg/day
Number of subjects: 149
Study 8297658 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 149
Study 3327677 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5mg twice daily
Number of subjects: 133
Study 3327677 — intervention group
Group type: COMPARATOR
Intervention: Moduretic mite every morning
Number of subjects: 133
Study 3327677 — intervention group
Group type: COMPARATOR
Intervention: Moduretic (after dose increase)
Number of subjects: 133
Study 29674706 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification using both fasting plasma glucose and HbA1c data
Number of subjects: 10000
Study 29674706 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired baseline measurements of fasting plasma glucose and HbA1c
Number of subjects: 10000
Study 25702630 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-down weight loss intervention
Number of subjects: 106
Study 25702630 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 106
Study 24884877 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical network-based intervention to improve uptake of guideline recommended care for men with high-risk prostate cancer following surgery.
Number of subjects: 9
Study 24884877 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians' knowledge and attitudes assessed through surveys.
Number of subjects: 9
Study 24884877 — intervention group
Group type: EXPERIMENTAL
Intervention: Process outcome measures assessed through document review.
Number of subjects: 9
Study 24884877 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews conducted to elucidate mechanisms of change.
Number of subjects: 9
Study 22709990 — intervention group
Group type: EXPERIMENTAL
Intervention: Chester step test (CST)
Number of subjects: 32
Study 22709990 — intervention group
Group type: COMPARATOR
Intervention: Modified incremental step test (MIST)
Number of subjects: 32
Study 20421547 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel of four kallikreins (total PSA, free PSA, intact PSA, hK2)
Number of subjects: 2914
Study 20421547 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of the kallikrein panel to 1,000 men with elevated PSA
Number of subjects: 2914
Study 18061415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed (aerobic and resistance) exercise programme (150 min/week) prescribed and supervised for 12 months
Number of subjects: 606
Study 18061415 — intervention group
Group type: COMPARATOR
Intervention: Conventional care including exercise counselling
Number of subjects: 606
Study 18061415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed (aerobic and resistance) exercise programme
Number of subjects: 606
Study 16086611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 732
Study 16086611 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs (fluoxetine, sertraline, paroxetine)
Number of subjects: 732
Study 16086611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732
Study 11338291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrilon Pepti
Number of subjects: 32
Study 11338291 — intervention group
Group type: EXPERIMENTAL
Intervention: Profylac
Number of subjects: 32
Study 11338291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nan HA
Number of subjects: 32
Study 9103485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone (10 mg, 15 mg, and 22.5 mg p.o.) after placebo or quinidine (100 mg) pretreatment
Number of subjects: 25
Study 9103485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9103485 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (100 mg) pretreatment
Number of subjects: 25
Study 7942523 — intervention group
Group type: COMPARATOR
Intervention: t‐PA plus saline solution (group 1)
Number of subjects: 47
Study 7942523 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA plus nitroglycerin (group 2)
Number of subjects: 47
Study 3035878 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimeldine, 100 mg, b.i.d., n = 40
Number of subjects: 75
Study 3035878 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline, 75 mg, b.i.d., n = 35
Number of subjects: 75
Study 29196928 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment (LT4 group)
Number of subjects: 140
Study 29196928 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (SCH group)
Number of subjects: 140
Study 26882324 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D social virtual world (avatar virtual interaction experimental condition)
Number of subjects: 90
Study 26882324 — intervention group
Group type: COMPARATOR
Intervention: 2D social networking site (no avatar virtual interaction control condition)
Number of subjects: 90
Study 26882324 — intervention group
Group type: COMPARATOR
Intervention: No intervention (no virtual interaction control condition)
Number of subjects: 90
Study 23125290 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (1 or 2 mg/m² · d during puberty)
Number of subjects: 88
Study 23125290 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment with additional GnRH analog (GnRHa) for 2 years
Number of subjects: 88
Study 23125290 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated short SGA adolescents)
Number of subjects: 88
Study 21645269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous DP-b99, 1.0 mg/kg/day for four consecutive days
Number of subjects: 770
Study 21645269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 770
Study 19489063 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose 1000 mg
Number of subjects: 60
Study 19489063 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study 16214379 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 109
Study 16214379 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 109
Study 16214379 — intervention group
Group type: COMPARATOR
Intervention: OARSI response criteria
Number of subjects: 109
Study 16214379 — intervention group
Group type: COMPARATOR
Intervention: Patient's global assessment
Number of subjects: 109
Study 16214379 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy vs Exercise therapy
Number of subjects: 109
Study 15330820 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg intramuscularly
Number of subjects: 7
Study 15330820 — intervention group
Group type: COMPARATOR
Intervention: Placebo intramuscularly
Number of subjects: 7
Study 11771747 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (5 mg patch)
Number of subjects: 8
Study 9203174 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-sensitive nephrotic syndrome (SSNS)
Number of subjects: 119
Study 9203174 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-resistant nephrotic syndrome
Number of subjects: 119
Study 9203174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephritic syndromes
Number of subjects: 119
Study 9203174 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with severe tubular abnormalities
Number of subjects: 119
Study 9203174 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight proteinuria
Number of subjects: 119
Study 9203174 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP
Number of subjects: 119
Study 8352356 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white morning light (more than 2500 lux)
Number of subjects: 30
Study 8352356 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white evening light (more than 2500 lux)
Number of subjects: 30
Study 8352356 — intervention group
Group type: COMPARATOR
Intervention: Placebo dim red evening light (less than 10 lux)
Number of subjects: 30
Study 3275568 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (300-450 mg/day)
Number of subjects: 9
Study 3275568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30109672 — intervention group
Group type: EXPERIMENTAL
Intervention: FTD (fotemustine, teniposide and dexamethasone)
Number of subjects: 49
Study 30109672 — intervention group
Group type: COMPARATOR
Intervention: HD-MA (high-dose methotrexate plus cytarabine)
Number of subjects: 49
Study 30109672 — intervention group
Group type: EXPERIMENTAL
Intervention: FTD
Number of subjects: 49
Study 30109672 — intervention group
Group type: COMPARATOR
Intervention: HD-MA
Number of subjects: 49
Study 28060012 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 292
Study 28060012 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated)
Number of subjects: 292
Study 28060012 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 292
Study 28060012 — intervention group
Group type: EXPERIMENTAL
Intervention: Controllers (both treated and untreated)
Number of subjects: 292
Study 25103870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab alone
Number of subjects: 82
Study 25103870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab with chemotherapy
Number of subjects: 82
Study 25103870 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 82
Study 22730954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 94
Study 22730954 — intervention group
Group type: COMPARATOR
Intervention: Supportive Listening
Number of subjects: 94
Study 22010780 — intervention group
Group type: EXPERIMENTAL
Intervention: Kudzu root extract
Number of subjects: 0
Study 22010780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18434299 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mm cryocatheter
Number of subjects: 160
Study 18434299 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm cryocatheter
Number of subjects: 160